ArticleBreast cancer research and treatment2025
Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the clinical benefit of the vinorelbine-gemcitabine every two weeks (VNR-GEMQ2W) regimen in patients with hormone receptor-positive (HR +)/HER2- advanced breast cancer (ABC) treated at a tertiary care hospital and with previous progression on cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i). STUDY
designA retrospective analysis was conducted on women treated for HR + /HER2-ABC, with VNR 25 mg/m
main outcome measuresProgression-free survival (PFS), overall response rate (ORR), overall survival, and treatment-related adverse events (AEs) evaluated according to CTCAE version 5.0 were retrospectively analyzed. A subanalysis of the data was performed based on major prognostic factors.
resultsA total of 53 patients were included, with a median age of 56.70 years. The majority had visceral metastases (81.13%). Patients had received a median of three prior lines of therapy - two lines of endocrine therapy and one line of chemotherapy. The median follow-up time was 28 months [interquartile range 15-34]. The median PFS was 4.27 months (95% confidence interval 3.25-6.34), and ORR was 18.87%. Grade ≥ 3 neutropenia was the most frequent severe AE (10.77%), with no treatment discontinuations due to toxicity. Only one case of grade 2 alopecia was reported (1.88%).
conclusionsAdministering after CDK4/6i and capecitabine, VNR-GEMQ2W regimen shows activity in HR + /HER2- ABC and a manageable safety profile. This regimen should be considered as a potential control arm in the design of future clinical trials targeting HR + /HER2- ABC.
Indexed as
Identifiers
41348333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.